Use of paroxetine during tamoxifen therapy for breast cancer was associated with increased breast-cancer and all-cause mortality
- SSRI use with tamoxifen. // OB/GYN Clinical Alert;Apr2010 Pharmacology, p1
The article reports on the results of the study on the effect of selective serotonine reuptake inhibitors (SSRI) paroxetine when used with tamoxifen on breast cancer patients. Researchers found that paroxetine reduces the effect of with tamoxifen leading to higher risk of death among breast...
- SSRI use with tamoxifen. // Primary Care Reports;Apr2010 Pharmacology Watch, p1
The article discusses research on selective serotonin reuptake inhibitors (SSRIs) paroxetine (Paxil), an anti-depressant drug that lessens the effect of tamoxifen in women with breast cancer. It references a study published in the "British Medical Journal," wherein the researchers observed more...
- SSRI use with tamoxifen. // Infectious Disease Alert;Apr2010 Pharmacology, p1
The article offers information on a "British Medical Journal" study that deals with the role of Selective Serotonin Reuptake Inhibitor (SSRI) paroxetine in reducing the effect of tamoxifen in women with breast cancer.
- Stratford 2010 relived. Sturdee, David // Menopause International;Sep2010, Vol. 16 Issue 3, p98
The article discusses the highlights of the 20th anniversary meeting of the British Menopause Society (BMS) held in Stratford-upon-Avon, England from June 24-25, 2010. The event's scientific programme focused on general health matters such as cardiovascular diseases (CVD) risk, metabolic...
- Paroxetine/tamoxifen interaction may increase mortality. // Reactions Weekly;2/13/2010, Issue 1288, p2
The article discusses research done on the association between the concomitant use of paroxetine during treatment with tamoxifen and an increased risk of breast cancer death by C. M. Kelly and colleagues, published in the 2010 online issue of the "British Medical Journal."
- Tamoxifen for women at high risk of breast cancer. Nazarali, Safia A.; Narod, Steven A. // Breast Cancer: Targets & Therapy;2014, Vol. 6, p29
Tamoxifen has been used as a treatment for women who have been diagnosed with breast cancer for roughly four decades and has been approved as chemoprevention for over ten years. Although tamoxifen has been proven to be beneficial in preventing breast cancer in high-risk women, its use has not...
- Effect of Systemic Adjuvant Treatment on Risk for Contralateral Breast Cancer in the Women's Environment, Cancer and Radiation Epidemiology Study. Bertelsen, Lisbeth; Bernstein, Leslie; Olsen, Jørgen H.; Meilemkjær, Lene; Haile, Robert W.; Lynch, Charles F.; Malone, Kathleen E.; Anton-Culver, Hoda; Christensen, Jane; Langholz, Bryan; Thomas, Duncan C.; Begg, Colin B.; Capanu, Marinela; Ejlertsen, Bent; Stovall, Marilyn; Boice Jr., John D.; Shore, Roy E. // JNCI: Journal of the National Cancer Institute;1/2/2008, Vol. 100 Issue 1, p32
Background: Results from randomized trials indicate that treatment with tamoxifen or chemotherapy for primary breast cancer reduces the risk for contralateral breast cancer. However, less is known about how long the risk is reduced and the impact of factors such as age and menopausal status....
- Anti-Estrogen Therapy May Reduce Lung Cancer Mortality. // Pulmonary Reviews;Feb2011, Vol. 16 Issue 2, p6
The article discusses the results of a study which confirms the efficacy of anti-breast cancer drug, Tamoxifen in reducing lung cancer risk and death in women.
- Study Shows New Breast Cancer Drug Letrozole Shrinks Tumors
More Effectively Than Tamoxifen. // Ascribe Newswire: Medicine;12/10/2001, p18
A new cancer drug called letrozole (trade name Femara) worked better at shrinking breast cancer tumors than did the front-line breast cancer drug tamoxifen among a group of postmenopausal women with estrogen-positive tumors, according to a study coordinated by a Duke University Medical Center...